The kallikrein-kinin system (KKS) is considered one of the therapeutic targets for diabetes and its complications. Ace Therapeutics is committed to helping clients accelerate the preclinical development of KKS-related drugs, aiming to provide safer and more effective therapeutic options for diabetes. Our professional team possesses extensive diabetes models and advanced technology platforms. We are committed to providing our clients with one-stop services from early discovery to preclinical evaluation to facilitate the efficient development and translation of KKS-related drugs.
Recent findings from human vitreous proteomics and experimental studies in animal models of diabetes suggest that KKS contributes to the pathogenesis of diabetes. The KKS may be involved in several pathogenic mechanisms leading to diabetic kidney disease (DKD), including oxidative stress, inflammatory cytokines, and pro-fibrotic profibrotic autacoids. Agents that activate the KKS have shown strong renal protective effects that might highlight its potential to change the clinical practice. In addition, activation of intraocular KKS induces retinal vascular permeability, vasodilation, and retinal thickening, and these responses are exacerbated in diabetic rats. These findings suggest that components of plasma KKS are potential therapeutic targets for diabetic macular edema. Thus, KKS is a target for the prevention and treatment of diabetes and its complications.
Fig.
1 The kallikrein-kinin system (KKS) components and protective effects of the KKS on diabetic nephropathy. (Tomita,
H. et al., 2012)
Ace Therapeutics accelerates candidate drug discovery by integrating diabetic models, pharmacological testing, and high-efficiency screening platforms to deliver customized R & D solutions. Our comprehensive preclinical capabilities enable efficient development and translation of KKS-based antidiabetic drugs.
KKS Research and Target Validation
We deeply investigate the composition of the KKS system and its physiological function in regulating oxidative stress, inflammatory response and so on. In addition, we validate its role in diabetic complications such as diabetic nephropathy and diabetic macular edema by developing appropriate diabetic models.
Drug Design and Screening based on the KKS
We employ structure-based drug design (SBDD) coupled with virtual screening (VS) and high-throughput screening (HTS) technologies to identify potential KKS-targeting compounds from extensive compound libraries. Our experts further optimize candidate molecules through quantitative structure-activity relationship (QSAR) modeling to enhance their selectivity and binding affinity.
Preclinical studies and evaluation of KKS-targeted antidiabetic drugs
We provide comprehensive preclinical research services including pharmacodynamic, pharmacokinetic, and toxicology studies to ensure the safety and efficacy of drug candidates. Our comprehensive in vitro and in vivo pharmacology testing is designed to help our clients screen novel antidiabetic drugs with high potency and low toxicity.
Ace Therapeutics accelerates the development of safe and effective antidiabetic drugs with advanced molecular design, efficacy modeling and metabolic research platforms. We are committed to applying our expertise to help our clients optimize their antidiabetic drug development. Please contact us for more details.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
